News

Tomato genome decoded
Enlarge image

ResearchUKSpainBelgiumItaly

Tomato genome decoded

31.05.2012 - Researchers have decoded the tomato genome, laying the foundation for smart breeding of other species of the solanaceae family.

Ghent, Rome, Harpenden, Washington – A consortium of 300 researchers from 14 countries has decoded 80% of the tomato genome, and 90% of its 35,000 protein-coding genes. The leaders of the UK arm of the Tomato Genome Consortium (TGC), Graham Seymour at the University of Nottingham and Gerard Bishop, formerly of Imperial College London, stressed the sequence will make precision breeding possible not just in tomatoes, but also in other crop species from the Solanaceae or nightshade family, such as aubergines and peppers.

They said it could help to develop tomato varieties that can survive pests, pathogens and even climate change, as well as high-yield crops that still have a good flavour. “It’s really all about making a better tomato,” commented Allen Van Deynze, a molecular geneticist at the Seed Biotechnology Center at the University of California, Davis. “This work enables a lot of things we just couldn’t do before.”

 The researchers compared the sequences a domesticated tomato variety used to produce the famous ketchup („Heinz1706“) and its closest wild relative, /Solanum pimpinellifolium/ and its functional consequences.  "For any characteristic of the tomato, whether it's taste, natural pest resistance or nutritional content, we've captured virtually all those genes," said James Giovannoni from the Boyce Thompson Institute for Plant Research at Cornell University, who was part of the U.S. tomato sequencing team.  The research also offers some insight into how the tomato ripens and how its relatives diversified and adapted to new environments.  Using traditional Sanger sequencing, the TGC started its work in 2003 but the genome sequence still had major holes by 2008. Next generation sequencing helped the consortium to close the gaps and to translate the genetic information into biological functions. Belgian experts from VIB and University Ghent mainly lead the gene prediction that translated the raw genome sequence in biological knowledge.

http://www.european-biotechnology-news.com/news/news/2012-02/tomato-genome-decoded.html

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

FinancingGermany

10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

Stock MarketsIrelandUK

05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.

LicencingDenmark

05.03.2015 Bavarian Nordic is outlicensing its Phase 3 prostate cancer immunotherapy Prostvac to pharma heavyweight Bristol Myers Squibb for a tidy €881m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS1.54 CHF14.07%
  • SYNGENTA329.00 CHF0.27%
  • 4SC0.84 EUR0.00%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • BASILEA110.00 CHF-2.65%
  • ACTELION114.70 CHF-1.88%

TOP

  • CYTOS1.54 CHF352.9%
  • MEDIGENE13.50 EUR217.6%
  • FORMYCON26.00 EUR55.7%

FLOP

  • WILEX2.92 EUR-14.9%
  • BASILEA110.00 CHF-10.0%
  • MORPHOSYS70.55 EUR-5.6%

TOP

  • SANTHERA95.40 CHF2346.2%
  • WILEX2.92 EUR386.7%
  • FORMYCON26.00 EUR273.6%

FLOP

  • CYTOS1.54 CHF-49.7%
  • 4SC0.84 EUR-37.3%
  • THERAMETRICS0.07 CHF-36.4%

No liability assumed, Date: 26.03.2015